Drugs that contain Temsirolimus
1. Torisel patents expiration
TORISEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44768 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
| US5362718 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5362718 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(4 years ago) | |
|
USRE44768 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(4 years ago) | |
| US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(8 months ago) | |
| US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(8 months ago) | |
| US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(8 months ago) | |
|
US8455539 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(2 months ago) | |
|
US8299116 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(2 months ago) | |
|
US8722700 (Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(2 months ago) | |
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(1 year, 8 months from now) | |
|
US8026276 (Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(2 years from now) | |
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(8 years from now) | |
|
US8791097 (Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | May 30, 2015 |
| M(M-92) | Jul 09, 2013 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-91) | Apr 26, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage
TORISEL family patents
